Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

30.45 +0.41 (+1.36%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,035,432
Open	30.24
Bid (Size)	28.00 (600)
Ask (Size)	31.50 (100)
Prev. Close	30.04
Today's Range	30.19 - 30.73
52wk Range	17.23 - 33.65
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗

November 18, 2025

Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.

Via Benzinga

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

From Genmab A/S

Via Business Wire

Performance

YTD	+45.0%	+45.0%
1 Month	+1.8%	+1.8%
3 Month	+23.5%	+23.5%
6 Month	+46.3%	+46.3%
1 Year	+48.8%	+48.8%

More News

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Via Investor's Business Daily

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 10, 2025

Via Benzinga

Analyst Expectations For Genmab's Future ↗

September 24, 2025

Via Benzinga

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Genmab A/S

Via Business Wire

Why Is Genmab Stock Trading Lower On Monday? ↗

October 20, 2025

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

October 18, 2025

From Genmab

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Why Genmab Stock Popped on Friday ↗

October 03, 2025

Via The Motley Fool

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

October 03, 2025

Via Chartmill

Why Genmab Stock Was Marching Higher Today ↗

September 30, 2025

Via The Motley Fool

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

September 29, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗

September 29, 2025

Via Benzinga

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗

September 29, 2025

Via Investor's Business Daily

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 03, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria ↗

September 03, 2025

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals ↗

September 01, 2025

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology ↗

August 28, 2025

Via Chartmill

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

August 26, 2025

From Genmab A/S

Via Business Wire

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Via Benzinga

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

August 07, 2025

From Genmab

Via Business Wire

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 30.45

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 11/21/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.